FCR Versus FC Alone in the Treatment of Chronic Lymphocytic Leukemia (CLL) in Relapsed Patients
Chronic Lymphocytic Leukemia
ClinicalTrials.gov recordTREATMENT READING
Source sections for this topic, with the original link and date. Patient and professional reading are labelled separately.
Not medical advice · Not a complete treatment or trial directory
Made by Triangle.
Selected text from the National Cancer Institute, with the original link and date. Made by Triangle. This page is not an NCI PDQ summary. Source topics may be broader than an individual diagnosis.
Source: Chronic Lymphocytic Leukemia Treatment (PDQ®)–Health Professional Version, National Cancer Institute.
Source updated: April 25, 2025. Captured 2026-09-09.
CT scans have a very limited role in monitoring patients after completion of treatment. CT scan or ultrasonography results determined the decision to treat for relapse in only 2 of 176 patients in three prospective trials for the German CLL Study Group.[67]
Sources: 67
This page is made by Triangle. The reading above is selected source text, not a treatment recommendation, and it is not medical advice.
Source: Chronic Lymphocytic Leukemia Treatment (PDQ®)–Health Professional Version, National Cancer Institute.
Source updated: April 25, 2025. Captured 2026-09-09.
Treatment of patients with chronic lymphocytic leukemia (CLL) must be individualized based on the clinical behavior of the disease.[1] Because this disease is generally not curable, occurs in an older population, and often progresses slowly, it is most often treated in a conservative fashion.[2]
In older trials with data collected from the 1970s through the 1990s, the median survival for all patients ranged from 8 to 12 years.[3,4] However, with the introduction of the B-cell receptor inhibitors and targeting of BCL2, the median survival for all patients has not been reached with over 10 years of follow-up.
Treatment of patients with CLL ranges from observation with treatment of infectious, hemorrhagic, or immunological complications to a variety of therapeutic options administered as single agents or combination therapy. In asymptomatic patients, treatment may be deferred until the disease progresses and symptoms occur.[3] Because the rate of progression may vary from patient to patient, with long periods of stability and sometimes spontaneous regressions, frequent and careful observation is required to monitor the clinical course.[5] Although even asymptomatic patients with del(17p) on fluorescence in situ hybridization (FISH) analysis (or those with a TP53 pathogenic variant) may be followed with watchful waiting, frequent monitoring may be required to avert rapid progression. A meta-analysis of randomized trials showed no survival benefit for immediate versus delayed therapy for patients with early-stage disease.[6][Level of evidence A1] For patients with progressing CLL, treatment will not be curative in most cases. Selected patients treated with allogeneic stem cell transplant have achieved prolonged disease-free survival (DFS), sometimes exceeding 20 years.[7-11] Prolonged DFS was also noted in young patients (<60 years) with IGH hypermutation who received the FCR regimen (fludarabine, cyclophosphamide, and rituximab).[12-14]
Sources: 3 · 5 · 6 · Level of evidence A1 · 7 · 11 · 12 · 14
The following clinical factors may be helpful in predicting progression of disease:[2]
Sources: 2
IGH pathogenic variant.
Chromosomal abnormalities found by FISH or cytogenetic analysis.
Beta-2-microglobulin.
Lymphocyte doubling time.
The International Workshop on Chronic Lymphocytic Leukemia defines symptomatic or progressive CLL as having the following signs and symptoms:[15]
Sources: 15
Evidence of progressive marrow failure—the development or worsening of anemia and/or thrombocytopenia (in some patients, platelet counts <100 × 109/L may remain stable over a long period; this does not automatically require therapeutic intervention). Cutoff levels of hemoglobin less than 10 g/dL or platelet counts less than 50 × 109/L are generally regarded as an indication for treatment.
Massive (i.e., ≥6 cm below the left costal margin), progressive, or symptomatic splenomegaly.
Massive lymph nodes (i.e., ≥10 cm in longest diameter), progressive, or symptomatic lymphadenopathy.
Progressive lymphocytosis with an increase of 50% or more over a 2-month period, or lymphocyte-doubling time (LDT) less than 6 months. LDT can be obtained by linear regression extrapolation of absolute lymphocyte counts obtained at intervals of 2 weeks over an observation period of 2 to 3 months; patients with initial blood lymphocyte counts less than 30 × 109/L may require a longer observation period to determine the LDT. Factors contributing to lymphocytosis other than CLL (e.g., infections or steroid administration) should be excluded.
Autoimmune complications, including anemia or thrombocytopenia that respond poorly to corticosteroids.
Symptomatic or functional extranodal involvement (e.g., skin, kidney, lung, or spine). Disease-related symptoms defined as any of the following:
Symptomatic or functional extranodal involvement (e.g., skin, kidney, lung, or spine). Disease-related symptoms defined as any of the following:
Unintentional weight loss of 10% or more within the previous 6 months.
Significant fatigue (i.e., Eastern Cooperative Oncology Group performance scale 2 or worse, cannot work, or unable to perform usual activities).
Fevers of 100.5°F or 38.0°C or higher for 2 or more weeks without evidence of infection.
Night sweats for at least 1 month without evidence of infection.
Source: Chronic Lymphocytic Leukemia Treatment (PDQ®)–Health Professional Version, National Cancer Institute.
Source updated: April 25, 2025. Captured 2026-09-09.
The following general principles may provide a sequencing for available therapeutic options:
Despite many therapeutic options, asymptomatic or minimally affected patients with CLL are often offered observation outside the context of a clinical trial. Therapy often begins when patients develop profound cytopenias, or when symptoms, such as enlarging bulky lymphadenopathy or debilitating symptoms, substantially impact their quality of life.
Because nontransplant curative therapy has not been found, the initial goal of therapy is to maximize efficacy (with improvement of overall survival), while introducing the least overall short- and long-term toxicity.
The U.S. Food and Drug Administration approved the biological agents ibrutinib, acalabrutinib, and venetoclax for first-line use in newly diagnosed patients with CLL who require therapy.[16] In patients with poor prognostic factors (especially those with del(17p) or TP53 pathogenic variants), ibrutinib, acalabrutinib, or venetoclax should be considered.[17]
Standard chemotherapeutic agents, such as fludarabine, bendamustine, cyclophosphamide, and chlorambucil, induce DNA damage that can manifest as more aggressive and refractory phenotypes upon relapse and can induce secondary malignancies. Yet, prolonged DFS (over 10 years) can be seen with the use of the FCR regimen in younger patients (<60 years) with IGH hypermutation.[12-14]
Standard chemotherapeutic agents, such as fludarabine, bendamustine, cyclophosphamide, and chlorambucil, induce DNA damage that can manifest as more aggressive and refractory phenotypes upon relapse and can induce secondary malignancies. Yet, prolonged DFS (over 10 years) can be seen with the use of the FCR regimen in younger patients (<60 years) with IGH hypermutation.[12-14]
Avoiding alkylating agents and purine analogues also prevents prolonged cytopenias and the recurrent, long-lasting, and sometimes fatal infections seen after therapy with these agents.
Avoiding chemotherapeutic agents up-front, when possible, is a new paradigm of sequencing therapy for CLL.
Older patients with comorbidities may better tolerate the newer biological agents (such as ibrutinib or venetoclax), monoclonal antibody therapy alone (such as high-dose rituximab), or dose modification of standard chemotherapeutic agents combined with rituximab. For older patients (>65 years), the combination of rituximab plus bendamustine (BR regimen) resulted in fewer adverse events and better outcomes than the FCR regimen.[18]
Sources: 18
Source: Chronic Lymphocytic Leukemia Treatment (PDQ®)–Health Professional Version, National Cancer Institute.
Source updated: April 25, 2025. Captured 2026-09-09.
Infectious complications in advanced disease are in part a consequence of the hypogammaglobulinemia and the inability to mount a humoral defense against bacterial or viral agents. Herpes zoster represents a frequent viral infection in these patients, but infections with Pneumocystis carinii and Candida albicans may also occur. The early recognition of infections and the institution of appropriate therapy are critical to the long-term survival of these patients. A randomized study of intravenous immunoglobulin (400 mg/kg every 3 weeks for 1 year) in patients with CLL and hypogammaglobulinemia produced significantly fewer bacterial infections and a significant delay in onset of first infection during the study period.[19] There was, however, no effect on survival. Routine chronic administration of intravenous immunoglobulin is expensive, and the long-term benefit (>1 year) is unproven.[20,21]
Patients with CLL who required hospitalization for COVID-19 prior to the induction of vaccines fared poorly regardless of stage in two retrospective reports.[22,23] One of the studies noted a protective effect from Bruton tyrosine kinase (BTK) inhibitors (usually ibrutinib),[23] but this was not seen in the other report.[22] With enhanced testing and the advent of multiple therapeutic strategies to prevent and treat COVID-19, the case fatality rate for patients with CLL dropped from 35% in early 2020 to 11% in late 2020 and early 2021 (P < .001).[22] For patients requiring hospitalization, the case fatality rate dropped from 40% to 20% (P = .003).
Autoimmune hemolytic anemia and/or thrombocytopenia can occur in patients with any stage of CLL.[24] Initial therapy involves corticosteroids with or without alkylating agents (fludarabine can worsen the hemolytic anemia). It is often necessary to control the autoimmune destruction with corticosteroids, if possible, before administering marrow-suppressive chemotherapy because it may be difficult for a patient to successfully receive a red blood cell or platelet transfusion. Alternate therapies include high-dose immune globulin, rituximab, cyclosporine, azathioprine, splenectomy, and low-dose radiation therapy to the spleen.[3,25] Tumor lysis syndrome is an uncommon complication (presenting in 1 of 300 patients) of chemotherapy for patients with bulky disease.[26]
Second malignancies and treatment-induced acute leukemias may also occur in a small percentage of patients.[27] Transformation of CLL to diffuse large B-cell lymphoma (DLBCL, known as Richter syndrome) occurs in 2% to 10% of patients. Risk factors for transformation include unmutated IGH, TP53 or NOTCH1 pathogenic variants, CDKN2A/B loss, and a complex karyotype.[28] Up to 60% to 70% of patients develop a DLBCL clonally related to the CLL, and these patients have a significantly worse prognosis than patients with de novo DLBCL.[29-31] Patients with a clonally unrelated DLBCL have a much better prognosis, which is similar to de novo DLBCL.[29] However, there is limited availability for real-life sequencing of the immunoglobulin heavy chains in the original CLL sample to compare with the transformed sample. Characteristic molecular signatures may serve as an alternate way to assess prognosis.[32] Up to 20% to 40% of patients with clonally related Richter syndrome are disease free for more than 5 years after aggressive combination chemotherapy, typically R-CHOP (rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone) or Pola-R-CHP (polatuzumab, rituximab, cyclophosphamide, doxorubicin, and prednisone), often followed by autologous or allogeneic stem cell transplant.[33-35] For more information, see Aggressive B-Cell Non-Hodgkin Lymphoma Treatment. In two retrospective reports, CLL with transformation to Hodgkin lymphoma had the same prognosis as de novo presentations of Hodgkin lymphoma at an equivalent age.[36,37][Level of evidence C3]
Sources: 27 · 28 · 29 · 31 · 29 · 32 · 33 · 35 · Aggressive B-Cell Non-Hodgkin Lymphoma Treatment · 36 · 37 · Level of evidence C3
The BTK inhibitors increased the risk of bleeding requiring hospitalization (3-year risk for patients who received ibrutinib, 8.8% [95% confidence interval (CI), 6.5%–11.7%]) and atrial fibrillation (3-year incidence for patients who received ibrutinib, 22.7% [95% CI, 19.0%–26.6%]).[38] A randomized trial with a median follow-up of 41 months showed less atrial fibrillation for patients with CLL who received acalabrutinib compared with ibrutinib (9.4% vs. 16%; P = .02).[39]
Source: Chronic Lymphocytic Leukemia Treatment (PDQ®)–Health Professional Version, National Cancer Institute.
Source updated: April 25, 2025. Captured 2026-09-09.
Source: Chronic Lymphocytic Leukemia Treatment (PDQ®)–Health Professional Version, National Cancer Institute.
Source updated: April 25, 2025. Captured 2026-09-09.
Source: Chronic Lymphocytic Leukemia Treatment (PDQ®)–Health Professional Version, National Cancer Institute.
Source updated: April 25, 2025. Captured 2026-09-09.
Because of its indolent nature, chemotherapy is not indicated for asymptomatic or minimally affected patients with CLL, and observation is the generally accepted approach.[1] Because the rate of progression may vary, with long periods of stability and sometimes spontaneous regressions, frequent and careful observation is required to monitor the clinical course. One nomogram to predict time-to-first treatment relies on the number of lymph node sites, size of cervical lymph nodes, lactate dehydrogenase level, the IGH mutational status, and the presence of del(11q) or del(17p) established by fluorescence in situ hybridization analysis.[2] Spontaneous regression, manifested by a sustained reduction of the malignant clone without therapy, occurs in less than 5% of patients. These patients almost exclusively have hypermutation of IGH.[3]
Evidence (observation):
The French Cooperative Group on Chronic Lymphocytic Leukemia randomly assigned 1,535 patients with previously untreated stage A disease to receive either chlorambucil or no immediate treatment.[4]
Sources: 4
The French Cooperative Group on Chronic Lymphocytic Leukemia randomly assigned 1,535 patients with previously untreated stage A disease to receive either chlorambucil or no immediate treatment.[4]
The results showed no survival advantage for immediate treatment with chlorambucil.[4][Level of evidence A1]
Sources: 4 · Level of evidence A1
A meta-analysis evaluated six trials of patients with early-stage CLL that involved immediate versus deferred therapy with chlorambucil (including the aforementioned trial by the French Cooperative Group).[5]
Sources: 5
A meta-analysis evaluated six trials of patients with early-stage CLL that involved immediate versus deferred therapy with chlorambucil (including the aforementioned trial by the French Cooperative Group).[5]
The results showed no difference in overall survival at 10 years.[5][Level of evidence A1]
Sources: 5 · Level of evidence A1
Despite many therapeutic options, observation should be considered for asymptomatic or minimally affected patients, even in the context of adverse prognostic findings. Therapy begins when patients develop profound cytopenias or when symptoms adversely impact quality of life.
There are no clinical trial results that confirm that immediate treatment of asymptomatic or minimally affected patients with the B-cell receptor inhibitors or BCL2 inhibitors is superior to observation.
Clinical trials will need to establish improved outcomes using the newer biological therapies in asymptomatic patients before observation or watchful waiting is discontinued.
Source: Chronic Lymphocytic Leukemia Treatment (PDQ®)–Health Professional Version, National Cancer Institute.
Source updated: April 25, 2025. Captured 2026-09-09.
Source: Chronic Lymphocytic Leukemia Treatment (PDQ®)–Health Professional Version, National Cancer Institute.
Source updated: April 25, 2025. Captured 2026-09-09.
The following regimens are considered first-line treatment approaches for patients with CLL who are experiencing symptomatic progression:
Bruton tyrosine kinase (BTK) inhibitors (acalabrutinib, zanubrutinib, or ibrutinib).
Sources: Bruton tyrosine kinase (BTK) inhibitors (acalabrutinib, zanubrutinib, or ibrutinib)
Venetoclax with initial use of obinutuzumab or rituximab.
Sources: Venetoclax with initial use of obinutuzumab or rituximab
Bendamustine and rituximab (BR).
Sources: Bendamustine and rituximab (BR)
Fludarabine, cyclophosphamide, and rituximab (FCR).
BTK inhibitor (ibrutinib or acalabrutinib) plus venetoclax.
Sources: BTK inhibitor (ibrutinib or acalabrutinib) plus venetoclax
R-CHOP (rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone) (only if Richter syndrome with histological progression is suspected clinically).
Source: Chronic Lymphocytic Leukemia Treatment (PDQ®)–Health Professional Version, National Cancer Institute.
Source updated: April 25, 2025. Captured 2026-09-09.
Source: Chronic Lymphocytic Leukemia Treatment (PDQ®)–Health Professional Version, National Cancer Institute.
Source updated: April 25, 2025. Captured 2026-09-09.
Evidence (ibrutinib vs. zanubrutinib):
A prospective randomized trial of 652 patients with relapsed or refractory CLL compared ibrutinib and zanubrutinib.[6]
Sources: 6
A prospective randomized trial of 652 patients with relapsed or refractory CLL compared ibrutinib and zanubrutinib.[6]
With a median follow-up of 29.6 months, the 2-year progression-free survival (PFS) rate was 78.4% in the zanubrutinib group and 65.9% in the ibrutinib group (hazard ratio [HR], 0.65; 95% confidence interval [CI], 0.49–0.86; P = .002).[6][Level of evidence B1]
Sources: 6 · Level of evidence B1
Cardiac disorders leading to treatment discontinuation occurred in 1 patient (0.3%) in the zanubrutinib group and 14 patients (4.3%) in the ibrutinib group. Six deaths caused by cardiac events were all in patients who received ibrutinib.
Source: Chronic Lymphocytic Leukemia Treatment (PDQ®)–Health Professional Version, National Cancer Institute.
Source updated: April 25, 2025. Captured 2026-09-09.
Evidence (ibrutinib vs. acalabrutinib):
A prospective randomized trial of 533 previously untreated patients compared the BTK inhibitors acalabrutinib and ibrutinib.[7]
Sources: 7
A prospective randomized trial of 533 previously untreated patients compared the BTK inhibitors acalabrutinib and ibrutinib.[7]
With a median follow-up of 41 months, acalabrutinib was noninferior to ibrutinib, with a median PFS of 38.4 months for patients in both arms of the trial (HR, 1.00; 95% CI, 0.79–1.27).[7][Level of evidence B1]
Sources: 7 · Level of evidence B1
The incidence of atrial fibrillation of any grade was lower for patients who received acalabrutinib than for patients who received ibrutinib (9.4% vs. 16.0%, P = .02). In this trial, the incidence of diarrhea and headaches was significantly higher in patients who received acalabrutinib (P < .05), while musculoskeletal pain was higher in patients who received ibrutinib (P = .0229).[8]
Sources: 8
Ventricular arrhythmias and sudden death events appear to be a side effect of all the BTK inhibitors. For acalabrutinib, these events occur with a relative risk of 8.2 over age-matched controls.[9]
Sources: 9
Source: Chronic Lymphocytic Leukemia Treatment (PDQ®)–Health Professional Version, National Cancer Institute.
Source updated: April 25, 2025. Captured 2026-09-09.
Evidence (ibrutinib vs. ibrutinib plus rituximab vs. BR):
A prospective trial included 547 previously untreated patients aged 65 years or older. Patients were randomly assigned to receive BR, ibrutinib alone, or ibrutinib plus rituximab.[10]
Sources: 10
A prospective trial included 547 previously untreated patients aged 65 years or older. Patients were randomly assigned to receive BR, ibrutinib alone, or ibrutinib plus rituximab.[10]
With a median follow-up of 38 months, the 2-year PFS rate was 74% for patients who received BR. The rates were significantly higher for patients who received ibrutinib alone (87%; HR, 0.39; 95% CI, 0.25–0.58) or ibrutinib plus rituximab (88%; HR, 0.38; 95% CI, 0.25–0.59; P < .001).[10][Level of evidence B1]
Sources: 10 · Level of evidence B1
There was no difference in PFS between the two ibrutinib groups (HR, 1.00; 95% CI, 0.62–1.62; P = .49) and no difference in overall survival (OS) between each of the groups.
Source: Chronic Lymphocytic Leukemia Treatment (PDQ®)–Health Professional Version, National Cancer Institute.
Source updated: April 25, 2025. Captured 2026-09-09.
Evidence (ibrutinib vs. rituximab plus ibrutinib):
A prospective randomized trial included 208 patients who were previously untreated or had relapsed disease. Patients received rituximab plus ibrutinib or ibrutinib alone.[11]
Sources: 11
A prospective randomized trial included 208 patients who were previously untreated or had relapsed disease. Patients received rituximab plus ibrutinib or ibrutinib alone.[11]
With a median follow-up of 36 months, there was no difference in PFS (86%; HR, 1.04; 95% CI, 0.49−2.20; P = .91).[11][Level of evidence B1]
Sources: 11 · Level of evidence B1
Source: Chronic Lymphocytic Leukemia Treatment (PDQ®)–Health Professional Version, National Cancer Institute.
Source updated: April 25, 2025. Captured 2026-09-09.
Ibrutinib is a selective irreversible inhibitor of BTK, a signaling molecule located upstream in the B-cell receptor-signaling cascade.
Evidence (ibrutinib vs. FCR):
ECOG-E1912 (NCT02048813) was a prospective randomized trial that compared ibrutinib and rituximab with FCR. A total of 529 patients previously untreated for CLL were randomly assigned in a 2:1 ratio to receive either ibrutinib and rituximab followed by ibrutinib maintenance (354 patients) or six cycles of FCR (175 patients).[12,13]
Sources: ECOG-E1912 · 12 · 13
ECOG-E1912 (NCT02048813) was a prospective randomized trial that compared ibrutinib and rituximab with FCR. A total of 529 patients previously untreated for CLL were randomly assigned in a 2:1 ratio to receive either ibrutinib and rituximab followed by ibrutinib maintenance (354 patients) or six cycles of FCR (175 patients).[12,13]
With a median follow-up of 5.8 years, the 5-year OS rate favored the ibrutinib arm (95% vs. 89%) (HR, 0.47; 95% CI, 0.25–0.89; P = .018).[13][Level of evidence A1]
Sources: 13 · Level of evidence A1
In 281 patients without IGH pathogenic variants, the 5-year PFS rate favored ibrutinib plus rituximab versus FCR (75% vs. 33%) (HR, 0.27; 95% CI, 0.18−0.41; P < .0001). In 114 patients with IGH pathogenic variants, the 5-year PFS rate was also significantly different, at 83% for the ibrutinib arm and 68% for the FCR arm (HR, 0.27; 95% CI, 0.11−0.62; P = .001).[12-14]
Although undetectable measurable residual disease (MRD) was less than 10% between 12 and 36 months follow-up, patients with detectable MRD did not have significantly worse PFS (P = .14 at 12 months, P = .90 at 24 months, and P = .53 at 36 months).[15]
Sources: 15
Source: Chronic Lymphocytic Leukemia Treatment (PDQ®)–Health Professional Version, National Cancer Institute.
Source updated: April 25, 2025. Captured 2026-09-09.
Evidence (zanubrutinib vs. BR):
A prospective randomized trial included 590 previously untreated patients aged 65 years or older. Patients were randomly assigned to receive zanubrutinib or BR.[16]
Sources: 16
A prospective randomized trial included 590 previously untreated patients aged 65 years or older. Patients were randomly assigned to receive zanubrutinib or BR.[16]
With a median follow-up of 26.2 months, the 2-year PFS rate was 85.5% (95% CI, 80.1%–89.6%) for patients who received zanubrutinib and 69.5% (95% CI, 62.4%–75.5%) for patients who received BR (HR, 0.42; 95% CI, 0.28–0.63; P < .0001).[16][Level of evidence B1]
Sources: 16 · Level of evidence B1
Source: Chronic Lymphocytic Leukemia Treatment (PDQ®)–Health Professional Version, National Cancer Institute.
Source updated: April 25, 2025. Captured 2026-09-09.
Acalabrutinib is a highly selective covalent irreversible BTK inhibitor, designed to minimize the gastrointestinal toxicities and risk of atrial fibrillation seen with ibrutinib.
Evidence (acalabrutinib plus obinutuzumab vs. acalabrutinib vs. chlorambucil plus obinutuzumab):
The prospective ELEVATE TN trial (NCT02475681) included 535 previously untreated patients aged 65 years or older with comorbidities (e.g., creatinine clearance <70 mL/min). Patients were randomly assigned to one of three arms: acalabrutinib plus obinutuzumab, acalabrutinib alone, or chlorambucil plus obinutuzumab.[17]
Sources: ELEVATE TN · 17
The prospective ELEVATE TN trial (NCT02475681) included 535 previously untreated patients aged 65 years or older with comorbidities (e.g., creatinine clearance <70 mL/min). Patients were randomly assigned to one of three arms: acalabrutinib plus obinutuzumab, acalabrutinib alone, or chlorambucil plus obinutuzumab.[17]
With a median follow-up of 28 months, the 24-month PFS rates were 93% for acalabrutinib plus obinutuzumab (HR, 0.10; 95% CI, 0.06−0.17; P < .0001), 87% for acalabrutinib alone (HR, 0.20; 95% CI, 0.13−0.30; P < .0001), and 47% for chlorambucil plus obinutuzumab.[17][Level of evidence B1]
Sources: 17 · Level of evidence B1
There was a small but significant difference in the PFS rates between the two acalabrutinib groups (93% vs. 87% at 24 months), which favored the combination (HR, 0.49; 95% CI, 0.26−0.95).[17]
Sources: 17
Source: Chronic Lymphocytic Leukemia Treatment (PDQ®)–Health Professional Version, National Cancer Institute.
Source updated: April 25, 2025. Captured 2026-09-09.
Source: Chronic Lymphocytic Leukemia Treatment (PDQ®)–Health Professional Version, National Cancer Institute.
Source updated: April 25, 2025. Captured 2026-09-09.
Evidence (venetoclax plus obinutuzumab vs. chlorambucil plus obinutuzumab):
The prospective CLL14 trial (NCT02242942) included 432 previously untreated patients with significant medical comorbidities (6 or higher on the Cumulative Illness Rating Scale; median age, 72 years). Patients were randomly assigned to receive either venetoclax (a highly selective inhibitor of BCL2) plus obinutuzumab (the human anti-CD20 monoclonal antibody) or chlorambucil plus obinutuzumab.[18]
The prospective CLL14 trial (NCT02242942) included 432 previously untreated patients with significant medical comorbidities (6 or higher on the Cumulative Illness Rating Scale; median age, 72 years). Patients were randomly assigned to receive either venetoclax (a highly selective inhibitor of BCL2) plus obinutuzumab (the human anti-CD20 monoclonal antibody) or chlorambucil plus obinutuzumab.[18]
With a median follow-up of 76.4 months, the median PFS rate was 76.2 months for venetoclax plus obinutuzumab, compared with 36.4 months for chlorambucil plus obinutuzumab (HR, 0.40; 95% CI, 0.31–0.52; P < .0001).[18][Level of evidence B1]
Sources: 18 · Level of evidence B1
The 6-year OS rate was 78.7% for venetoclax plus obinutuzumab and 69.2% for chlorambucil plus obinutuzumab (HR, 0.69; 95% CI, 0.48–1.01; P = .052).
Source: Chronic Lymphocytic Leukemia Treatment (PDQ®)–Health Professional Version, National Cancer Institute.
Source updated: April 25, 2025. Captured 2026-09-09.
Evidence (VenR vs. BR):
The prospective MURANO trial (NCT02005471) included 389 patients with relapsed or refractory CLL. Patients were randomly assigned to receive either VenR (venetoclax for 2 years plus rituximab for the first 6 months) or 6 months of BR.
Sources: MURANO
The prospective MURANO trial (NCT02005471) included 389 patients with relapsed or refractory CLL. Patients were randomly assigned to receive either VenR (venetoclax for 2 years plus rituximab for the first 6 months) or 6 months of BR.
With a median follow-up of 24 months, the 2-year PFS rate was 84.9% for VenR and 36.3% for BR (HR, 0.17; 95% CI, 0.11–0.25; P < .001).[19,20] An update with a 48-month median follow-up, reported in abstract form, showed a 4-year OS rate of 85.3% for VenR and 66.8% for BR (HR, 0.41; 95% CI, 0.26−0.65; P < .0001).[21][Level of evidence A1]
Sources: 19 · 20 · 21 · Level of evidence A1
With a median follow-up of 59.2 months, the 5-year OS rate was 82.1% (95% CI, 76.4%–87.8%) for patients who received VenR and 62.2% (95% CI, 54.8%–69.6%) for patients who received BR (P < .0001).[22][Level of evidence A1] The median time to next treatment was 57.8 months (95% CI, 55.1–not estimable) for VenR.
Sources: 22 · Level of evidence A1
For the 43% of patients assigned to VenR who achieved undetectable MRD at the end of treatment, the median time to MRD conversion was 19.4 months. The median time from MRD conversion to overt clinical progressive disease was another 25.2 months.[22]
Sources: 22
Source: Chronic Lymphocytic Leukemia Treatment (PDQ®)–Health Professional Version, National Cancer Institute.
Source updated: April 25, 2025. Captured 2026-09-09.
Source: Chronic Lymphocytic Leukemia Treatment (PDQ®)–Health Professional Version, National Cancer Institute.
Source updated: April 25, 2025. Captured 2026-09-09.
Evidence (BR vs. FCR):
The German CLL Study Group compared BR versus FCR as first-line therapy in patients with CLL who required therapy.[23]
Sources: 23
The German CLL Study Group compared BR versus FCR as first-line therapy in patients with CLL who required therapy.[23]
With a median follow-up of 37.1 months, the median PFS was better for patients who received FCR (55.2 months vs. 41.7 months) (HR, 1.64; 90% CI, 1.31–2.06; P = .001), but there was no difference in the OS rate at 3 years (91% vs. 92%, not significant).[23][Level of evidence B1]
Sources: 23 · Level of evidence B1
In patients older than 65 years, there was no difference in PFS between the two arms, but more infections occurred with FCR than with BR (grade 3 to 5 infection, 47% vs. 27%).
Source: Chronic Lymphocytic Leukemia Treatment (PDQ®)–Health Professional Version, National Cancer Institute.
Source updated: April 25, 2025. Captured 2026-09-09.
Source: Chronic Lymphocytic Leukemia Treatment (PDQ®)–Health Professional Version, National Cancer Institute.
Source updated: April 25, 2025. Captured 2026-09-09.
FCR is used for patients with an IGH hypermutation.
Evidence (FCR):
Several trials used FCR for appropriate patients with IGH pathogenic variants who required therapy.
Several trials used FCR for appropriate patients with IGH pathogenic variants who required therapy.
The PFS rate exceeded 60% at more than 10 years.[24-26][Level of evidence C2] Nonetheless, late relapses were seen beyond 10 years.
Sources: 24 · 26 · Level of evidence C2
Source: Chronic Lymphocytic Leukemia Treatment (PDQ®)–Health Professional Version, National Cancer Institute.
Source updated: April 25, 2025. Captured 2026-09-09.
Source: Chronic Lymphocytic Leukemia Treatment (PDQ®)–Health Professional Version, National Cancer Institute.
Source updated: April 25, 2025. Captured 2026-09-09.
Evidence (BTK inhibitor [ibrutinib or acalabrutinib] plus venetoclax):
A prospective randomized trial included 523 patients with previously untreated CLL. Patients received either ibrutinib plus venetoclax for up to 6 years or FCR for six cycles.[27] This comparison was embedded in a larger three-arm randomization that also included ibrutinib alone for up to 6 years; the statistics were thought too preliminary to analyze the ibrutinib-alone group versus the other arms.
Sources: 27
A prospective randomized trial included 523 patients with previously untreated CLL. Patients received either ibrutinib plus venetoclax for up to 6 years or FCR for six cycles.[27] This comparison was embedded in a larger three-arm randomization that also included ibrutinib alone for up to 6 years; the statistics were thought too preliminary to analyze the ibrutinib-alone group versus the other arms.
With a median follow-up of 43.7 months, the 3-year OS rate was 98.0% (95% CI, 95.2%–99.2%) in the ibrutinib-plus-venetoclax group and 93.0% (95% CI, 88.9%–95.6%) in the FCR group (HR, 0.31; 95% CI, 0.15–0.67).[27][Level of evidence A1]
Sources: 27 · Level of evidence A1
The 3-year OS benefit favored ibrutinib plus venetoclax (HR, 0.23; 95% CI, 0.06–0.81) for patients without IGH pathogenic variants, but not for those with IGH pathogenic variants (HR, 0.61; 95% CI, 0.20–1.82).
The 3-year PFS rate was 97.2% (95% CI, 94.1%–98.6%) in the ibrutinib-plus-venetoclax group and 76.8% (95% CI, 70.8%–81.7%) in the FCR group (HR, 0.13; 95% CI, 0.07–0.24; P < .001).
MRD negativity was a requirement for stopping therapy with venetoclax and ibrutinib after 2 years. This trial did not randomly assign patients to either continued therapy or cessation of therapy based on MRD status. The utility and value of MRD could not be determined from this trial due to its design.
A prospective randomized trial (GLOW [NCT03462719]) included 211 patients with previously untreated CLL. Patients were aged 65 and older or aged 18 to 64 with comorbidities and an Eastern Cooperative Oncology Group performance status of 0 to 2. Patients were randomly assigned to receive either fixed-duration ibrutinib and venetoclax (15 months total) or chlorambucil and obinutuzumab (6 months total).[28]
A prospective randomized trial (GLOW [NCT03462719]) included 211 patients with previously untreated CLL. Patients were aged 65 and older or aged 18 to 64 with comorbidities and an Eastern Cooperative Oncology Group performance status of 0 to 2. Patients were randomly assigned to receive either fixed-duration ibrutinib and venetoclax (15 months total) or chlorambucil and obinutuzumab (6 months total).[28]
With a median follow-up of 46 months, the 42-month PFS rate was 74.6% in the ibrutinib-plus-venetoclax group and 24.8% in the chlorambucil-plus-obinutuzumab group (HR, 0.214; 95% CI, 0.138–0.334; P < .0001).[28][Level of evidence B1]
Sources: 28 · Level of evidence B1
Ibrutinib was given for 3 months prior to the combination of venetoclax with ibrutinib to avoid tumor lysis syndrome.
At 3 months after the end of therapy, 40.6% of patients who received ibrutinib and venetoclax achieved undetectable MRD (<10-5 by next-generation sequencing) in the bone marrow, and 43.4% of patients achieved undetectable MRD in the peripheral blood.[28] However, the PFS rate exceeded 90% at 12 months after the end of therapy regardless of if the MRD was detectable or not.
Sources: 28
A prospective trial included 867 patients with previously untreated CLL. Patients were randomly assigned to one of three treatment regimens: (1) AV (acalabrutinib and venetoclax), (2) AVO (acalabrutinib, venetoclax, and obinutuzumab), or (3) either BR or FCR (at the discretion of the investigator).[29]
Sources: 29
A prospective trial included 867 patients with previously untreated CLL. Patients were randomly assigned to one of three treatment regimens: (1) AV (acalabrutinib and venetoclax), (2) AVO (acalabrutinib, venetoclax, and obinutuzumab), or (3) either BR or FCR (at the discretion of the investigator).[29]
With a median follow-up of 41 months, the 3-year OS rate was 94.1% for patients who received AV and 85.9% for patients who received BR or FCR (HR, 0.33; 95% CI, 0.18–0.56; P < .0001). However, the 3-year OS rate was 87.7% for patients who received AVO compared with 85.9% for patients who received BR or FCR (HR, 0.76; 95% CI, 0.49–1.18; P = nonsignificant).[29][Level of evidence A1]
Sources: 29 · Level of evidence A1
The 3-year PFS rate was 76.5% for patients who received AV, 83.1% for patients who received AVO, and 66.5% for patients who received BR or FCR. The PFS for patients who received AV versus those who received BR or FCR had an HR of 0.65 (95% CI, 0.49–0.87; P = .004). The PFS for patients who received AVO versus those who received BR or FCR had an HR of 0.42 (95% CI, 0.30–0.59; P < .001).
Although treatment with AVO resulted in a better PFS than AV, there were increased infectious deaths with AVO, especially from COVID-19 (SARS-CoV-2). These deaths accounted for a nonsignificant difference in OS rates between patients who received AVO (87.7%) and patients who received BR or FCR (85.9%).
A phase II trial included 80 previously untreated patients who were aged 65 or older or had high-risk disease. Patients were treated with ibrutinib for 3 months followed by combined ibrutinib plus venetoclax for a total of 24 months.[30]
Sources: 30
A phase II trial included 80 previously untreated patients who were aged 65 or older or had high-risk disease. Patients were treated with ibrutinib for 3 months followed by combined ibrutinib plus venetoclax for a total of 24 months.[30]
With a median follow-up of 38.5 months, the 2-year response rate was 82%, the 3-year PFS rate was 93% (95% CI, 88%–99%), and the 3-year OS rate was 96%.[30][Level of evidence C1]
Sources: 30 · Level of evidence C1
The toxicity of the combination is similar to either agent alone and avoids the tumor lysis syndrome seen when starting with venetoclax.
High rates of undetectable MRD (<10-4 by 8-color flow cytometry) in the peripheral blood (75%) and bone marrow (72%) is unprecedented. The clinical significance of this finding awaits prospective randomized trials to establish clinical outcomes versus either drug alone. This combination has also been tested in the relapsed/refractory setting.[31]
Sources: 31
A phase II trial included 159 previously untreated patients aged 70 years or older. Patients received 3 cycles of ibrutinib alone followed by 12 cycles of ibrutinib plus venetoclax.[32]
Sources: 32
A phase II trial included 159 previously untreated patients aged 70 years or older. Patients received 3 cycles of ibrutinib alone followed by 12 cycles of ibrutinib plus venetoclax.[32]
With a median follow-up of 27.9 months, the complete response rate was 55% (95% CI, 48%–63%), the undetectable MRD rate was 77% (95% CI, 70%–83%) for blood and 60% (95% CI, 52%–67%) for bone marrow, the 2-year PFS rate was 95% (95% CI, 90%–97%), and the 2-year OS rate was 98% (95% CI, 94%–99%).[32][Level of evidence C1]
Sources: 32 · Level of evidence C1
The toxicity of the ibrutinib-venetoclax combination was similar to either agent alone, and the ibrutinib-alone lead-in avoided tumor lysis syndrome.
A phase II trial included 41 previously untreated patients who received ibrutinib plus venetoclax and obinutuzumab. Patients with undetectable MRD at cycle 16 could opt to discontinue treatment if they had a complete response.[33]
Sources: 33
A phase II trial included 41 previously untreated patients who received ibrutinib plus venetoclax and obinutuzumab. Patients with undetectable MRD at cycle 16 could opt to discontinue treatment if they had a complete response.[33]
With a median follow-up of 38.4 months, the 3-year PFS rate was 79.9% and the 3-year OS rate was 92.6%.[33][Level of evidence C1]
Sources: 33 · Level of evidence C1
In summary, these trials establish the use of venetoclax with obinutuzumab or rituximab, or the use of ibrutinib, acalabrutinib, or zanubrutinib as first-line therapy in patients with previously untreated CLL. A lower rate of atrial fibrillation occurs with acalabrutinib or zanubrutinib than with ibrutinib.[6,7,34,35] Unlike ibrutinib or acalabrutinib, which are given continuously until relapse, venetoclax may be stopped after 12 months, with durable maintenance of remission. Venetoclax, ibrutinib, acalabrutinib, or zanubrutinib can be readministered with success, if needed.[35,36] These targeting drugs are also effective for patients with TP53 pathogenic variants.[37] Different regimens of these drugs, as standalone agents or in combinations, with or without obinutuzumab, need to be evaluated in prospective randomized trials. Several provocative phase II and III trials with these combinations have resulted in unprecedented rates of MRD-negative disease which appear more durable;[30,38-41] whether this results in any clinical advantage to a more sequential approach requires prospective randomized trials. The National Comprehensive Cancer Network has listed the combination of venetoclax and ibrutinib as a first-line treatment option for patients with previously untreated CLL.[42] The considerable financial toxicity of these combinations mandates verification of superior efficacy. These trials further establish the rationale for a chemotherapy-free approach for first-line therapy for CLL instead of the previous standard of BR and FCR (which proved more efficacious than chlorambucil regimens). Patients at the highest risk of relapse have multiple poor prognostic factors, including TP53 pathogenic variants, elevated lactate dehydrogenase, elevated beta-2 microglobulin, and prior treatment.[43] These highest risk patients should consider clinical trials.
Sources: 6 · 7 · 34 · 35 · 35 · 36 · 37 · 30 · 38 · 41 · 42 · 43
Source: Chronic Lymphocytic Leukemia Treatment (PDQ®)–Health Professional Version, National Cancer Institute.
Source updated: April 25, 2025. Captured 2026-09-09.
Undetectable MRD (≤1 × 10-4 CLL cells in peripheral blood or bone marrow aspirates) can be confirmed by flow cytometry or next-generation sequencing. The attainment of undetectable MRD represents an even more stringent complete remission that was prognostic for improved PFS and OS in multiple studies.[22,44-46]The use of time-limited therapy with venetoclax, or the investigational combination of venetoclax and a BTK inhibitor, has produced complete responses, and even undetectable MRD, in most patients.[22,44,47]
Testing for undetectable MRD has become a standard parameter for defining responses in all modern clinical trials for CLL. Undetectable MRD has prognostic value but its status as a predictive marker is uncertain. The potential value of MRD testing in routine clinical practice depends on whether it can be used for clinical decision making such as stopping, changing, or continuing treatment. High-level evidence for this intervention would require a prospective randomized clinical trial in which MRD was used as a predictive biomarker for a group attaining an OS advantage compared with a control group disregarding MRD status. Such evidence has not been attained. Similar to outcomes in follicular lymphoma and other indolent lymphoid neoplasms, improved PFS in patients with CLL does not directly predict OS.
A phase II trial used a combination of venetoclax and ibrutinib in patients with undetectable MRD after 1 year of therapy. Patients were randomly assigned to receive either ibrutinib maintenance therapy or treatment cessation.[47] All MRD-positive patients continued to receive ibrutinib. With a median follow-up of 34.4 months, the 1-year PFS rates were 98% for patients with undetectable MRD who ceased therapy, 96% for patients with undetectable MRD who received continued ibrutinib, and 97% for MRD-positive patients who received continued ibrutinib. All patients did well at 12 months. Knowledge of MRD status to guide discontinuation of therapy did not affect the outcome.[47]
Another phase II trial included 70 previously untreated patients who received 1 year of venetoclax plus obinutuzumab. Patients were randomly assigned to receive another year of venetoclax irrespective of MRD status, or another year of venetoclax only if they were MRD-positive. With a median follow-up of 35.2 months, the MRD rates were identical for both randomized groups, suggesting no improved efficacy with this approach, although increased adverse events were reported with an extra year of venetoclax.[48]
Sources: 48
Before MRD is used outside the context of a clinical trial, conclusive evidence is required to establish that MRD is a predictive biomarker that can guide clinical decisions.
Source: Chronic Lymphocytic Leukemia Treatment (PDQ®)–Health Professional Version, National Cancer Institute.
Source updated: April 25, 2025. Captured 2026-09-09.
Source: Chronic Lymphocytic Leukemia Treatment (PDQ®)–Health Professional Version, National Cancer Institute.
Source updated: April 25, 2025. Captured 2026-09-09.
The same regimens considered for first-line therapy for patients with CLL can be readministered in a sequential fashion. These regimens are described in more detail under first-line therapy. For more information, see the Treatment of Symptomatic or Progressive CLL section.
Bruton tyrosine kinase (BTK) inhibitors (acalabrutinib, zanubrutinib, or ibrutinib).
Venetoclax with initial use of obinutuzumab or rituximab.
Bendamustine and rituximab (BR).
Fludarabine, cyclophosphamide, and rituximab (FCR).
BTK inhibitor (ibrutinib or acalabrutinib) plus venetoclax.
R-CHOP (rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone) (only if Richter syndrome with histological progression is suspected clinically).
In the relapsed setting, venetoclax showed similar efficacy and safety even after previous therapy with ibrutinib or idelalisib (the phosphatidylinositol 3-kinase [PI3K] delta inhibitor).[1,2]
Source: Chronic Lymphocytic Leukemia Treatment (PDQ®)–Health Professional Version, National Cancer Institute.
Source updated: April 25, 2025. Captured 2026-09-09.
Unlike other BTK inhibitors (ibrutinib, acalabrutinib, and zanubrutinib), pirtobrutinib binds to BTK in a noncovalent manner.[6]
Sources: 6
In a prospective phase I/II study, 317 patients with CLL/small lymphocytic leukemia received pirtobrutinib. A total of 247 of these patients had been treated previously with a covalent-binding BTK inhibitor.[7]
Sources: 7
In a prospective phase I/II study, 317 patients with CLL/small lymphocytic leukemia received pirtobrutinib. A total of 247 of these patients had been treated previously with a covalent-binding BTK inhibitor.[7]
With a median follow-up of 19.4 months, the median progression-free survival (PFS) was 19.6 months (95% confidence interval [CI], 16.9–22.1) for all patients and 16.8 months (95% CI, 13.2–18.7) for the subgroup of patients with BTK inhibitor resistance, intolerance, or BTK C481 variants (a resistance variant for the covalent agents).[7][Level of evidence C3]
Sources: 7 · Level of evidence C3
In this trial, 82 patients had a diagnosis of Richter transformation. Among those patients, the overall response rate was 50.0% (95% CI, 38.7%–61.3%), and the complete response rate was 13%.[8][Level of evidence C3]
Sources: 8 · Level of evidence C3
Source: Chronic Lymphocytic Leukemia Treatment (PDQ®)–Health Professional Version, National Cancer Institute.
Source updated: April 25, 2025. Captured 2026-09-09.
Autologous T cells can be modified by viral vectors to incorporate antigen receptor specificity for the B-cell antigen CD19 and then infused into previously treated patients.[9] A dramatic response lasting 6 months has prompted larger trials of this concept. Ongoing clinical trials are testing the concept of T cells directed at CD19 with engineered CAR T cells.[10-12]
Source: Chronic Lymphocytic Leukemia Treatment (PDQ®)–Health Professional Version, National Cancer Institute.
Source updated: April 25, 2025. Captured 2026-09-09.
Idelalisib is an oral inhibitor of the delta isoform of PI3K, which is in the B-cell receptor-signaling cascade. This drug has been withdrawn from its U.S. Food and Drug Administration (FDA) indication due to toxicity and is no longer available. Duvelisib is an oral dual inhibitor of the delta and gamma isoforms of PI3K.[13]
Sources: 13
In a prospective trial, 319 patients with relapsed and refractory CLL/small lymphocytic lymphoma were randomly assigned to receive duvelisib versus ofatumumab.[14]
Sources: 14
In a prospective trial, 319 patients with relapsed and refractory CLL/small lymphocytic lymphoma were randomly assigned to receive duvelisib versus ofatumumab.[14]
With a median follow-up of 22.4 months, the median PFS was significantly higher for patients who received duvelisib, at 13.3 months, than for patients who received ofatumumab, at 9.9 months (hazard ratio [HR], 0.52; P < .0001).[14][Level of evidence B1]
Sources: 14 · Level of evidence B1
Serious side effects include infections, pneumonitis, diarrhea or colitis, dermatitis, neutropenia, rash, fatigue, pyrexia, nausea, anemia, and transaminitis.
The FDA has approved duvelisib for third-line (or greater) use. However, follow-up data submitted to the FDA showed, with a median follow-up of 63 months, a median OS of 52.3 months (95% CI, 41.8–68.0) in the duvelisib group and 63.3 months (95% CI, 41.2–not estimable) in the ofatumumab group.[15]
Sources: 15
Source: Chronic Lymphocytic Leukemia Treatment (PDQ®)–Health Professional Version, National Cancer Institute.
Source updated: April 25, 2025. Captured 2026-09-09.
Lenalidomide is an oral immunomodulatory agent with response rates of more than 50%, with or without rituximab, for patients with previously treated and untreated disease.[16-22][Level of evidence C3] Prolonged, lower-dose approaches and attention to prevention of tumor lysis syndrome are suggested with this agent.[16,23] Combination therapy and long-term toxicities from using lenalidomide (such as increased myelodysplasia, as seen in myeloma patients) remain undefined for patients with CLL.
Sources: 16 · 22 · Level of evidence C3 · 16 · 23
Source: Chronic Lymphocytic Leukemia Treatment (PDQ®)–Health Professional Version, National Cancer Institute.
Source updated: April 25, 2025. Captured 2026-09-09.
In a prospective randomized trial, 241 previously untreated patients younger than 66 years with advanced-stage disease received induction therapy with a CHOP (cyclophosphamide, doxorubicin, vincristine, and prednisone)-based regimen followed by fludarabine.[24] Complete responders (105 patients) were randomly assigned to undergo autologous stem cell transplant (SCT) or observation, while the other 136 patients were randomly assigned to receive dexamethasone, high-dose cytarabine, and cisplatin reinduction followed by either autologous SCT or fludarabine plus cyclophosphamide (FC). Although the 3-year event-free survival (EFS) favored autologous SCT in complete responders, there was no difference in OS in any of the randomized comparisons.[24][Level of evidence B1] Autologous bone marrow/stem cell transplant is rarely employed for patients with relapsed CLL.
Sources: 24 · 24 · Level of evidence B1
Patients with adverse prognostic factors are very likely to die from CLL. These patients are candidates for clinical trials that employ high-dose chemotherapy and immunotherapy with myeloablative or nonmyeloablative allogeneic peripheral blood SCT.[25-30] Although most patients who attain complete remission after autologous SCT eventually relapse, a survival plateau for allogeneic SCT suggests an additional graft-versus-leukemia effect.[30] A series (NCT00281983) of 90 patients with relapsed or refractory CLL who underwent allogeneic SCT reported a 6-year OS rate of 58% and a 6-year EFS rate of 38%, which included patients with the worst prognostic factors (such as a TP53 pathogenic variant).[31][Level of evidence C2]
Sources: 25 · 30 · 30 · NCT00281983 · 31 · Level of evidence C2
Source: Chronic Lymphocytic Leukemia Treatment (PDQ®)–Health Professional Version, National Cancer Institute.
Source updated: April 25, 2025. Captured 2026-09-09.
Ofatumumab is a humanized anti-CD20 monoclonal antibody.
Evidence (ofatumumab alone and in combination with chlorambucil):
A prospective trial included 474 previously treated patients who attained partial or complete remission to second- or third-line chemotherapy. Patients were randomly assigned to 2 years of maintenance therapy with ofatumumab versus observation.[32]
Sources: 32
A prospective trial included 474 previously treated patients who attained partial or complete remission to second- or third-line chemotherapy. Patients were randomly assigned to 2 years of maintenance therapy with ofatumumab versus observation.[32]
With a median follow-up of 19 months, median PFS favored the ofatumumab maintenance arm, at 29.4 months versus 15.2 months (HR, 0.50; 95% CI, 0.38–0.66; P < .0001). There was no difference in OS.[32][Level of evidence B1]
Sources: 32 · Level of evidence B1
A prospective randomized trial of 447 patients who were previously untreated compared ofatumumab plus chlorambucil with chlorambucil alone.[33]
Sources: 33
A prospective randomized trial of 447 patients who were previously untreated compared ofatumumab plus chlorambucil with chlorambucil alone.[33]
With a median follow-up of 2 years, median PFS favored the ofatumumab plus chlorambucil arm, at 22.4 months versus 13.1 months (HR, 0.57; 95% CI, 0.45–0.72; P = .0001). There was no difference in OS.[33][Level of evidence B1]
Sources: 33 · Level of evidence B1
Source: Chronic Lymphocytic Leukemia Treatment (PDQ®)–Health Professional Version, National Cancer Institute.
Source updated: April 25, 2025. Captured 2026-09-09.
Relatively low doses of radiation therapy can be administered for lymphadenopathy that causes problems due to size or encroachment on adjacent organs. Sometimes radiation therapy to one nodal area or the spleen will result in an abscopal effect (i.e., the shrinkage of lymph nodes in untreated sites).
Source: Chronic Lymphocytic Leukemia Treatment (PDQ®)–Health Professional Version, National Cancer Institute.
Source updated: April 25, 2025. Captured 2026-09-09.
Alemtuzumab is no longer available commercially in the United States for neoplastic indications but can be obtained from the pharmaceutical company on a compassionate-use basis (Lemtrada REMS [Risk Evaluation and Mitigation Strategy] Program).
Sources: Lemtrada REMS [Risk Evaluation and Mitigation Strategy] Program
Alemtuzumab, the monoclonal antibody directed at CD52, shows activity in the setting of chemotherapy-resistant disease or high-risk untreated patients with del(17p) or TP53 pathogenic variants.[34-36] As a single agent, the subcutaneous route of delivery is preferred to the intravenous route in patients because of the similar efficacy and decreased adverse effects, including less acute allergic reactions that were shown in some nonrandomized reports.[36-40]
In a combination regimen, subcutaneous alemtuzumab plus fludarabine (with or without cyclophosphamide) or intravenous alemtuzumab plus alkylating agents have resulted in excess infectious toxicities and death, with no compensatory improvement in efficacy in three phase II trials and one randomized trial.[41-43][Level of evidence C3]; [44][Level of evidence B1]
Sources: 41 · 43 · Level of evidence C3 · 44 · Level of evidence B1
Source: Chronic Lymphocytic Leukemia Treatment (PDQ®)–Health Professional Version, National Cancer Institute.
Source updated: April 25, 2025. Captured 2026-09-09.
These references have been identified by members of the PDQ Adult Treatment Editorial Board as significant in the field of chronic lymphocytic leukemia (CLL) treatment. This list is provided to inform users of important studies that have helped shape the current understanding of and treatment options for CLL. Listed after each reference are the sections within this summary where the reference is cited.
Sources: PDQ Adult Treatment Editorial Board
Seymour JF, Kipps TJ, Eichhorst BF, et al.: Four-year analysis of Murano study confirms sustained benefit of time-limited venetoclax-rituximab (VenR) in relapsed/refractory (R/R) chronic lymphocytic leukemia (CLL). [Abstract] Blood 134 (Suppl 1): A-355, 2019.Cited in:
Seymour JF, Kipps TJ, Eichhorst BF, et al.: Four-year analysis of Murano study confirms sustained benefit of time-limited venetoclax-rituximab (VenR) in relapsed/refractory (R/R) chronic lymphocytic leukemia (CLL). [Abstract] Blood 134 (Suppl 1): A-355, 2019.Cited in:
Treatment of Symptomatic or Progressive Chronic Lymphocytic Leukemia
Sources: Treatment of Symptomatic or Progressive Chronic Lymphocytic Leukemia
Seymour JF, Kipps TJ, Eichhorst B, et al.: Venetoclax-Rituximab in Relapsed or Refractory Chronic Lymphocytic Leukemia. N Engl J Med 378 (12): 1107-1120, 2018. [PUBMED Abstract] Cited in:
Sources: [PUBMED Abstract]
Seymour JF, Kipps TJ, Eichhorst B, et al.: Venetoclax-Rituximab in Relapsed or Refractory Chronic Lymphocytic Leukemia. N Engl J Med 378 (12): 1107-1120, 2018. [PUBMED Abstract] Cited in:
Treatment of Symptomatic or Progressive Chronic Lymphocytic Leukemia
Sources: Treatment of Symptomatic or Progressive Chronic Lymphocytic Leukemia
Shanafelt TD, Wang XV, Kay NE, et al.: Ibrutinib-Rituximab or Chemoimmunotherapy for Chronic Lymphocytic Leukemia. N Engl J Med 381 (5): 432-443, 2019. [PUBMED Abstract]Cited in:
Sources: [PUBMED Abstract]
Shanafelt TD, Wang XV, Kay NE, et al.: Ibrutinib-Rituximab or Chemoimmunotherapy for Chronic Lymphocytic Leukemia. N Engl J Med 381 (5): 432-443, 2019. [PUBMED Abstract]Cited in:
Treatment of Symptomatic or Progressive Chronic Lymphocytic Leukemia
Sources: Treatment of Symptomatic or Progressive Chronic Lymphocytic Leukemia
Shanafelt TD, Wang V, Kay NE, et al.: Ibrutinib and rituximab provides superior clinical outcome compared to FCR in younger patients with chronic lymphocytic leukemia (CLL): extended follow-up from the E1912 trial. [Abstract] Blood 134 (Suppl 1): A-33, 2019.Cited in:
Shanafelt TD, Wang V, Kay NE, et al.: Ibrutinib and rituximab provides superior clinical outcome compared to FCR in younger patients with chronic lymphocytic leukemia (CLL): extended follow-up from the E1912 trial. [Abstract] Blood 134 (Suppl 1): A-33, 2019.Cited in:
Treatment of Symptomatic or Progressive Chronic Lymphocytic Leukemia
Sources: Treatment of Symptomatic or Progressive Chronic Lymphocytic Leukemia
Al-Sawaf O, Zhang C, Tandon M, et al.: Venetoclax plus obinutuzumab versus chlorambucil plus obinutuzumab for previously untreated chronic lymphocytic leukaemia (CLL14): follow-up results from a multicentre, open-label, randomised, phase 3 trial. Lancet Oncology 21 (9): 1188-1200, 2020. [PUBMED Abstract]Cited in:
Sources: [PUBMED Abstract]
Al-Sawaf O, Zhang C, Tandon M, et al.: Venetoclax plus obinutuzumab versus chlorambucil plus obinutuzumab for previously untreated chronic lymphocytic leukaemia (CLL14): follow-up results from a multicentre, open-label, randomised, phase 3 trial. Lancet Oncology 21 (9): 1188-1200, 2020. [PUBMED Abstract]Cited in:
Treatment of Symptomatic or Progressive Chronic Lymphocytic Leukemia
Sources: Treatment of Symptomatic or Progressive Chronic Lymphocytic Leukemia
Thompson PA, Tam CS, O'Brien SM, et al.: Fludarabine, cyclophosphamide, and rituximab treatment achieves long-term disease-free survival in IGHV-mutated chronic lymphocytic leukemia. Blood 127 (3): 303-9, 2016. [PUBMED Abstract]Cited in:
Sources: [PUBMED Abstract]
Thompson PA, Tam CS, O'Brien SM, et al.: Fludarabine, cyclophosphamide, and rituximab treatment achieves long-term disease-free survival in IGHV-mutated chronic lymphocytic leukemia. Blood 127 (3): 303-9, 2016. [PUBMED Abstract]Cited in:
Selection of Therapy for Chronic Lymphocytic Leukemia
Sources: Selection of Therapy for Chronic Lymphocytic Leukemia
Treatment of Symptomatic or Progressive Chronic Lymphocytic Leukemia
Sources: Treatment of Symptomatic or Progressive Chronic Lymphocytic Leukemia
Source: Chronic Lymphocytic Leukemia Treatment (PDQ®)–Patient Version, National Cancer Institute.
Source updated: October 15, 2024. Captured 2026-09-09.
The prognosis depends on:
Sources: prognosis
Whether there are certain gene changes, such as in TP53 or IGH.
Whether lymphocytes have spread throughout the bone marrow.
Whether the red blood cell and platelet counts are low.
Whether the white blood cell count is increasing quickly.
The stage of the cancer.
Sources: stage
The results of certain blood tests, such as the beta-2 microglobulin and lactate dehydrogenase tests.
Sources: beta-2 microglobulin · lactate dehydrogenase
The patient's age and general health.
How quickly and how low the leukemia cell count drops during treatment.
Whether the CLL gets better with treatment or has recurred (come back).
Whether the CLL progresses to lymphoma or becomes prolymphocytic leukemia.
Sources: progresses · prolymphocytic leukemia
Whether the patient gets another type of cancer after being diagnosed with CLL.
Treatment options depend on:
The red blood cell, white blood cell, and platelet blood counts.
The age and health of the patient at the time of diagnosis.
Whether there are signs or symptoms, such as fever, chills, or weight loss.
The response to initial treatment.
Sources: response
Whether the CLL has recurred (come back).
Sources: recurred
Source: Chronic Lymphocytic Leukemia Treatment (PDQ®)–Patient Version, National Cancer Institute.
Source updated: October 15, 2024. Captured 2026-09-09.
Source: Chronic Lymphocytic Leukemia Treatment (PDQ®)–Patient Version, National Cancer Institute.
Source updated: October 15, 2024. Captured 2026-09-09.
There are different types of treatment for patients with chronic lymphocytic leukemia (CLL).
The following types of treatment are used:
The following types of treatment are used:
Watchful waiting
Targeted therapy
Chemotherapy
Radiation therapy
Immunotherapy
Chemotherapy with bone marrow or peripheral blood stem cell transplant
New types of treatment are being tested in clinical trials.
Treatment for chronic lymphocytic leukemia may cause side effects.
Patients may want to think about taking part in a clinical trial.
Patients can enter clinical trials before, during, or after starting their cancer treatment.
Follow-up care may be needed.
Source: Chronic Lymphocytic Leukemia Treatment (PDQ®)–Patient Version, National Cancer Institute.
Source updated: October 15, 2024. Captured 2026-09-09.
Different types of treatment are available for patients with CLL. Some treatments are standard (the currently used treatment), and some are being tested in clinical trials. A treatment clinical trial is a research study meant to help improve current treatments or obtain information on new treatments for patients with cancer. When clinical trials show that a new treatment is better than the standard treatment, the new treatment may become the standard treatment. Patients may want to think about taking part in a clinical trial. Some clinical trials are open only to patients who have not started treatment.
Sources: standard · clinical trials · research study
Source: Chronic Lymphocytic Leukemia Treatment (PDQ®)–Patient Version, National Cancer Institute.
Source updated: October 15, 2024. Captured 2026-09-09.
Source: Chronic Lymphocytic Leukemia Treatment (PDQ®)–Patient Version, National Cancer Institute.
Source updated: October 15, 2024. Captured 2026-09-09.
Watchful waiting is closely monitoring a patient's condition without giving any treatment until signs or symptoms appear or change. This is also called observation. Watchful waiting is used to treat asymptomatic and symptomatic or progressive CLL.
Sources: signs · symptoms · asymptomatic · symptomatic · progressive · CLL
Source: Chronic Lymphocytic Leukemia Treatment (PDQ®)–Patient Version, National Cancer Institute.
Source updated: October 15, 2024. Captured 2026-09-09.
Targeted therapy is a type of treatment that uses drugs or other substances to identify and attack specific cancer cells. Different types of targeted therapy are used to treat CLL:
Sources: Targeted therapy
Tyrosine kinase inhibitor (TKI) therapy: This treatment blocks the enzyme, tyrosine kinase, that causes stem cells to develop into more white blood cells than the body needs. Ibrutinib, acalabrutinib, zanubrutinib, and duvelisib are TKIs used to treat symptomatic or progressive, recurrent, or refractory CLL.
Sources: Tyrosine kinase inhibitor · enzyme · stem cells · white blood cells · Ibrutinib · acalabrutinib · zanubrutinib · duvelisib · recurrent · refractory
BCL2 inhibitor therapy: This treatment blocks a protein called BCL2, which is found on some leukemia cells. This may kill leukemia cells and make them more sensitive to other anticancer drugs. Venetoclax is a type of BCL2 therapy used to treat symptomatic or progressive, recurrent, or refractory CLL.
Sources: BCL2 · protein · leukemia cells · Venetoclax
Monoclonal antibody therapy: Monoclonal antibodies are immune system proteins made in the laboratory to treat many diseases, including cancer. As a cancer treatment, these antibodies can attach to a specific target on cancer cells or other cells that may help cancer cells grow. The antibodies are able to then kill the cancer cells, block their growth, or keep them from spreading. Monoclonal antibodies are given by infusion. They may be used alone or to carry drugs, toxins, or radioactive material directly to cancer cells. Rituximab, ofatumumab, obinutuzumab, and alemtuzumab alone and in combination with chemotherapy are used to treat symptomatic or progressive, recurrent, or refractory CLL.
Sources: Monoclonal antibody · immune system · antibodies · infusion · radioactive · Rituximab · ofatumumab · obinutuzumab · alemtuzumab
For more information, see Drugs Approved for Chronic Lymphocytic Leukemia.
Source: Chronic Lymphocytic Leukemia Treatment (PDQ®)–Patient Version, National Cancer Institute.
Source updated: October 15, 2024. Captured 2026-09-09.
Chemotherapy is a cancer treatment that uses drugs to stop the growth of cancer cells, either by killing the cells or by stopping them from dividing. When chemotherapy is taken by mouth or injected into a vein or muscle, the drugs enter the bloodstream and can reach cancer cells throughout the body (systemic chemotherapy). Combination chemotherapy is treatment using more than one anticancer drug.
Sources: injected
For more information, see Drugs Approved for Chronic Lymphocytic Leukemia.
Source: Chronic Lymphocytic Leukemia Treatment (PDQ®)–Patient Version, National Cancer Institute.
Source updated: October 15, 2024. Captured 2026-09-09.
Radiation therapy is a cancer treatment that uses high-energy x-rays or other types of radiation to kill cancer cells or keep them from growing. External radiation therapy uses a machine outside the body to send radiation toward the area of the body with cancer, such as a group of lymph nodes or the spleen. This treatment may be used to reduce pain related to a swollen spleen or lymph nodes.
Sources: x-rays · radiation · lymph nodes · spleen
Source: Chronic Lymphocytic Leukemia Treatment (PDQ®)–Patient Version, National Cancer Institute.
Source updated: October 15, 2024. Captured 2026-09-09.
Immunotherapy is a treatment that uses the patient's immune system to fight cancer. Substances made by the body or made in a laboratory are used to boost, direct, or restore the body's natural defenses against cancer.
Sources: Immunotherapy · immune system
Immunomodulating agent: Lenalidomide stimulates T cells to kill leukemia cells. It may be used alone or with rituximab in patients with symptomatic or progressive, recurrent, or refractory CLL.
Sources: Immunomodulating agent · Lenalidomide · T cells · rituximab
CAR T-cell therapy: This treatment changes the patient's T cells (a type of immune system cell) so they will attack certain proteins on the surface of cancer cells. T cells are taken from the patient and special receptors are added to their surface in the laboratory. The changed cells are called chimeric antigen receptor (CAR) T cells. The CAR T cells are grown in the laboratory and given to the patient by infusion. The CAR T cells multiply in the patient's blood and attack cancer cells. CAR T-cell therapy is being studied in the treatment of recurrent or refractory CLL.
Sources: CAR T-cell therapy · T cells · proteins · receptors · chimeric antigen receptor · infusion
Source: Chronic Lymphocytic Leukemia Treatment (PDQ®)–Patient Version, National Cancer Institute.
Source updated: October 15, 2024. Captured 2026-09-09.
Chemotherapy is given to kill cancer cells. Healthy cells, including blood-forming cells, are destroyed by the cancer treatment. A bone marrow or peripheral blood stem cell transplant are treatments to replace the blood-forming cells. Stem cells (immature blood cells) are removed from the blood or bone marrow of the patient or a donor and are frozen and stored. After the patient completes chemotherapy, the stored stem cells are thawed and given back to the patient through an infusion. These reinfused stem cells grow into (and restore) the body's blood cells.
Sources: bone marrow · peripheral blood stem cell · Stem cells · donor
Source: Chronic Lymphocytic Leukemia Treatment (PDQ®)–Patient Version, National Cancer Institute.
Source updated: October 15, 2024. Captured 2026-09-09.
Information about clinical trials is available from the NCI website.
Sources: NCI website
Source: Chronic Lymphocytic Leukemia Treatment (PDQ®)–Patient Version, National Cancer Institute.
Source updated: October 15, 2024. Captured 2026-09-09.
For information about side effects caused by treatment for cancer, visit our Side Effects page.
Sources: side effects · Side Effects
Source: Chronic Lymphocytic Leukemia Treatment (PDQ®)–Patient Version, National Cancer Institute.
Source updated: October 15, 2024. Captured 2026-09-09.
For some patients, taking part in a clinical trial may be the best treatment choice. Clinical trials are part of the cancer research process. Clinical trials are done to find out if new cancer treatments are safe and effective or better than the standard treatment.
Sources: clinical trial · standard treatment
Many of today's standard treatments for cancer are based on earlier clinical trials. Patients who take part in a clinical trial may receive the standard treatment or be among the first to receive a new treatment.
Patients who take part in clinical trials also help improve the way cancer will be treated in the future. Even when clinical trials do not lead to effective new treatments, they often answer important questions and help move research forward.
Source: Chronic Lymphocytic Leukemia Treatment (PDQ®)–Patient Version, National Cancer Institute.
Source updated: October 15, 2024. Captured 2026-09-09.
Some clinical trials only include patients who have not yet received treatment. Other trials test treatments for patients whose cancer has not gotten better. There are also clinical trials that test new ways to stop cancer from recurring (coming back) or reduce the side effects of cancer treatment.
Sources: side effects
Clinical trials are taking place in many parts of the country. Information about clinical trials supported by NCI can be found on NCI’s clinical trials search webpage. Clinical trials supported by other organizations can be found on the ClinicalTrials.gov website.
Sources: clinical trials search · ClinicalTrials.gov
Source: Chronic Lymphocytic Leukemia Treatment (PDQ®)–Patient Version, National Cancer Institute.
Source updated: October 15, 2024. Captured 2026-09-09.
As you go through treatment, you will have follow-up tests or check-ups. Some tests that were done to diagnose or stage the cancer may be repeated to see how well the treatment is working. Decisions about whether to continue, change, or stop treatment may be based on the results of these tests.
Some of the tests will continue to be done from time to time after treatment has ended. The results of these tests can show if your condition has changed or if the cancer has recurred (come back).
Source: Chronic Lymphocytic Leukemia Treatment (PDQ®)–Patient Version, National Cancer Institute.
Source updated: October 15, 2024. Captured 2026-09-09.
For information about the treatment listed below, see the Treatment Option Overview section.
Sources: Treatment Option Overview
The treatment of asymptomatic chronic lymphocytic leukemia (CLL) may include watchful waiting.
Sources: asymptomatic · chronic lymphocytic leukemia · watchful waiting
Source: Chronic Lymphocytic Leukemia Treatment (PDQ®)–Patient Version, National Cancer Institute.
Source updated: October 15, 2024. Captured 2026-09-09.
For information about the treatments listed below, see the Treatment Option Overview section.
Sources: Treatment Option Overview
The treatment of symptomatic or progressive chronic lymphocytic leukemia (CLL) may include the following:
Sources: symptomatic · progressive · chronic lymphocytic leukemia
Watchful waiting.
Sources: Watchful waiting
Targeted therapy with any of the following drugs:
Sources: Targeted therapy
Targeted therapy with any of the following drugs:
A tyrosine kinase inhibitor (acalabrutinib, zanubrutinib, or ibrutinib).
Sources: tyrosine kinase inhibitor · acalabrutinib · zanubrutinib · ibrutinib
Venetoclax with obinutuzumab or rituximab.
Sources: Venetoclax · obinutuzumab · rituximab
Chemotherapy and rituximab.
Sources: Chemotherapy
Immunotherapy (lenalidomide) with or without rituximab.
Sources: Immunotherapy · lenalidomide
A clinical trial of bone marrow or peripheral blood stem cell transplantation.
Sources: clinical trial · bone marrow · peripheral blood stem cell · transplantation
All of these treatments may be used for patients being treated for the first time and those who have been treated before. Because these treatments have not been compared in studies, it is not possible to know if one treatment is better than another. The choice of treatment is made based on test results, the patient's age and general health, and the desire to minimize short-term and long-term side effects.
Sources: short-term · long-term side effects
Source: Chronic Lymphocytic Leukemia Treatment (PDQ®)–Patient Version, National Cancer Institute.
Source updated: October 15, 2024. Captured 2026-09-09.
For information about the treatments listed below, see the Treatment Option Overview section.
Sources: Treatment Option Overview
The treatment of recurrent or refractory chronic lymphocytic leukemia (CLL) may include therapies and clinical trials.
Sources: recurrent · refractory · chronic lymphocytic leukemia · clinical trials
Targeted therapy with any of the following drugs:
Sources: Targeted therapy
Targeted therapy with any of the following drugs:
A tyrosine kinase inhibitor (acalabrutinib, zanubrutinib, or ibrutinib).
Sources: tyrosine kinase inhibitor · acalabrutinib · zanubrutinib · ibrutinib
Venetoclax with or without obinutuzumab or rituximab.
Sources: Venetoclax · obinutuzumab · rituximab
Ofatumumab with or without chemotherapy.
Sources: Ofatumumab
Duvelisib.
Sources: Duvelisib
Chemotherapy with or without rituximab.
Sources: Chemotherapy
Immunotherapy (lenalidomide) with or without rituximab.
Sources: Immunotherapy · lenalidomide
Bone marrow or peripheral blood stem cell transplantation.
Sources: Bone marrow · peripheral blood stem cell · transplantation
Radiation therapy as palliative treatment to relieve symptoms and improve quality of life.
Sources: Radiation therapy · palliative treatment · symptoms · quality of life
A clinical trial of CAR T-cell therapy.
Sources: clinical trial · CAR T-cell therapy
Chronic Lymphocytic Leukemia
ClinicalTrials.gov recordLeukemia
ClinicalTrials.gov recordChronic Lymphocytic Leukemia
ClinicalTrials.gov recordLymphocytic Leukemia, Chronic
ClinicalTrials.gov recordB-cell Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma
ClinicalTrials.gov recordLymphocytic Leukemia, Chronic
ClinicalTrials.gov recordChronic Lymphocytic Leukemia, Non-Hodgkin Lymphoma
ClinicalTrials.gov recordChronic Lymphocytic Leukemia
ClinicalTrials.gov recordRelapsed or Refractory Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma
ClinicalTrials.gov recordChronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma
ClinicalTrials.gov recordChronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma
ClinicalTrials.gov recordChronic Lymphocytic Leukemia, 17p Deletion, Cancer of the Blood and Bone Marrow
ClinicalTrials.gov recordChronic Lymphocytic Leukemia
ClinicalTrials.gov recordChronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma
ClinicalTrials.gov recordChronic Lymphocytic Leukemia
ClinicalTrials.gov recordAnemia, Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma
ClinicalTrials.gov recordChronic Lymphocytic Leukemia
ClinicalTrials.gov recordLymphocytic Leukemia, Chronic
ClinicalTrials.gov recordChronic Lymphocytic Leukemia, Small-Cell Lymphoma
ClinicalTrials.gov recordChronic Lymphocytic Leukemia
ClinicalTrials.gov recordChronic Lymphocytic Leukemia
ClinicalTrials.gov recordLeukemia, Lymphocytic, Chronic, B-Cell, Lymphoma, Small Lymphocytic
ClinicalTrials.gov recordChronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma
ClinicalTrials.gov recordLeukemia, Lymphocytic, Chronic, B-Cell
ClinicalTrials.gov recordChronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma
ClinicalTrials.gov recordChronic Lymphocytic Leukemia, Waldenstrom Macroglobulinemia, Mantle Cell Lymphoma, Marginal Zone Lymphoma, B-cell Lymphoma, Small Lymphocytic Lymphoma
ClinicalTrials.gov recordChronic Lymphocytic Leukemia
ClinicalTrials.gov recordChronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma
ClinicalTrials.gov recordB-cell Chronic Lymphocytic Leukemia, Recurrent Small Lymphocytic Lymphoma, Refractory Chronic Lymphocytic Leukemia, Waldenström Macroglobulinemia
ClinicalTrials.gov recordLeukemia, Lymphoma
ClinicalTrials.gov recordAcute Myelogenous Leukemia, Acute Lymphocytic Leukemia, Chronic Myelogenous Leukemia, Chronic Lymphocytic Leukemia, Myelodysplastic Syndromes, Multiple Myeloma, Non-Hodgkins...
ClinicalTrials.gov recordAcute Myelogenous Leukemia, Acute Lymphocytic Leukemia, Chronic Myelogenous Leukemia, Chronic Lymphocytic Leukemia, Myelodysplasia, Lymphoma, Non-Hodgkin's, Mantle-Cell...
ClinicalTrials.gov recordLeukemia, Lymphoma
ClinicalTrials.gov recordB-cell Chronic Lymphocytic Leukemia, Multiple Myeloma
ClinicalTrials.gov recordAcute Myelogenous Leukemia, Lymphoid Leukemia, Chronic Myelogenous Leukemia, Malignant Lymphoma, Hodgkin's Disease, Chronic Lymphocytic Leukemia, Myeloproliferative Disorder,...
ClinicalTrials.gov recordExtranodal Marginal Zone Lymphoma of Mucosa-Associated Lymphoid Tissue, Nodal Marginal Zone Lymphoma, Recurrent Grade 1 Follicular Lymphoma, Recurrent Grade 2 Follicular...
ClinicalTrials.gov recordHematologic Malignancies
ClinicalTrials.gov recordMonoclonal Gammopathy of Undetermined Significance, Smoldering Multiple Myeloma, Chronic Lymphocytic Leukemia
ClinicalTrials.gov recordAcute Myelogenous Leukemia, Acute Lymphocytic Leukemia, Chronic Myelogenous Leukemia, Chronic Lymphocytic Leukemia, Myelodysplasia, Non-Hodgkin's Lymphoma, Hodgkin's Disease,...
ClinicalTrials.gov recordHematologic Neoplasms
ClinicalTrials.gov recordHematological Malignancies
ClinicalTrials.gov recordNon-Hodgkin's Lymphoma, Hodgkin's Lymphoma, Multiple Myeloma, Chronic Lymphocytic Leukemia, Acute Myelogenous Leukemia
ClinicalTrials.gov recordHematologic Malignancy, Leukemia, Acute Lymphoblastic Leukemia, ALL, Acute Myelogenous Leukemia, AML, Chronic Lymphocytic Leukemia, CLL, Lymphoma, Hodgkin's Lymphoma,...
ClinicalTrials.gov recordHematological Malignancies
ClinicalTrials.gov recordChronic Lymphocytic Leukemia
ClinicalTrials.gov recordAcute Myelogenous Leukemia (AML), Acute Lymphoblastic Leukemia (ALL), Myelodysplastic Syndromes (MDS), Lymphoma, Myeloma, Chronic Lymphocytic Leukemia (CLL), Chronic...
ClinicalTrials.gov recordSingle Umbilical Cord Blood Transplantation, Non-myeloablative Conditioning, Acute Lymphocytic Leukemia, Myelodysplastic Syndrome, Non-Hodgkin's Lymphoma, Multiple Myeloma,...
ClinicalTrials.gov recordRecurrent B-Cell Non-Hodgkin Lymphoma, Recurrent Chronic Lymphocytic Leukemia, Recurrent Extranodal Marginal Zone Lymphoma of Mucosa-Associated Lymphoid Tissue, Recurrent Grade...
ClinicalTrials.gov recordLymphoma, Large B-Cell, Diffuse, Lymphoma, Mantle-Cell, Lymphoma, Follicular, Cancer, Neoplasm, Tumor, Lymphoma, Malignant, Lymphoma, B-cell, Lymphoma, Non-Hodgkin, B-Cell...
ClinicalTrials.gov recordChronic Myelogenous Leukemia, Acute Myelogenous Leukemia, Myelodysplastic Syndrome, Acute Lymphocytic Leukemia, Chronic Lymphocytic Leukemia, Hodgkin's Lymphoma, Non-Hodgkin's...
ClinicalTrials.gov recordHodgkin's Lymphoma, Lymphoid Leukemia, Lymphoma, Leukemia, Myeloma, Acute Lymphocytic Leukemia, Non Hodgkin Lymphoma, Chronic Lymphocytic Leukemia, Multiple Myeloma, Chronic...
ClinicalTrials.gov recordNon-Hodgkin Lymphoma, Burkitt's Lymphoma, Chronic Lymphocytic Leukemia, Lymphoma, Large B-Cell, Diffuse, Lymphoma, Follicular, Lymphoma, Mantle-Cell, Lymphoma, Marginal Zone,...
ClinicalTrials.gov recordMyelodysplastic Syndrome (MDS), Chronic Lymphocytic Leukemia (CLL), Chemotherapy-sensitive Lymphoma, Acute Lymphoblastic Leukemia (ALL)/T Lymphoblastic Lymphoma, Acute...
ClinicalTrials.gov recordB-cell Lymphoma, Chronic Lymphocytic Leukaemia, Waldenström Macroglobulinemia
ClinicalTrials.gov recordAcute Lymphoblastic Leukemia, Burkitt Lymphoma, Natural Killer Cell Malignancies, Chronic Myelogenous Leukemia, Myelodysplastic Syndromes, Large-cell Lymphoma, Chronic...
ClinicalTrials.gov recordChronic Lymphocytic Leukemia (CLL), Waldenstrom Macroglobulinemia (WM)
ClinicalTrials.gov recordSecondary Immunodeficiencies (SID)
ClinicalTrials.gov recordB-Cell Prolymphocytic Leukemia, Chronic Lymphocytic Leukemia, Peripheral T-Cell Lymphoma, Primary Cutaneous T-Cell Non-Hodgkin Lymphoma, Sezary Syndrome, T-Cell Prolymphocytic...
ClinicalTrials.gov recordMultiple Myeloma, AL Amyloidosis, Chronic Lymphocytic Leukemia
ClinicalTrials.gov recordChronic lymphocytic leukemia refractory to fludarabine and alemtuzumab
Adult patients with relapsed/ refractory chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL) in patients who have received at least two prior lines of therapy including a Bruton’s tyrosine kinase (BTK) inhibitor and a...
1.2 Chronic Lymphocytic Leukemia (CLL) or Small Lymphocytic Lymphoma (SLL) BREYANZI is indicated for the treatment of adult patients with relapsed or refractory chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL) who...
Chronic Lymphocytic Leukemia
COPIKTRA is a kinase inhibitor indicated for the treatment of adult patients with relapsed or refractory chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL) after at least two prior lines lines of systemic therapy.
1 INDICATIONS AND USAGE COPIKTRA is indicated for the treatment of adult patients with relapsed or refractory chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL) after at least two prior lines of systemic therapy.
Chronic lymphocytic leukemia after at least one prior therapy
1.1 Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma IMBRUVICA is indicated for the treatment of adult patients with chronic lymphocytic leukemia (CLL)/small lymphocytic lymphoma (SLL). 1. 2 Chronic Lymphocytic Leukemia/Small...
1.2 Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma JAYPIRCA is indicated for the treatment of adult patients with relapsed or refractory chronic lymphocytic leukemia or small lymphocytic lymphoma (CLL/SLL) who have previously...
Adult patients with chronic lymphocytic leukemia or small lymphocytic lymphoma (CLL/SLL) who have received at least two prior lines of therapy, including a BTK inhibitor and a BCL-2 inhibitor
For adults with B-cell CLL that has not responded to or progressed during or after treatment with at least one standard alkylating agent containing regimen
Treatment of Recurrent or Refractory Chronic Lymphocytic Leukemia
1 INDICATIONS AND USAGE RITUXAN HYCELA is a combination of rituximab, a CD20-directed cytolytic antibody, and hyaluronidase human, an endoglycosidase, indicated for the treatment of adult patients with: Follicular Lymphoma (FL) ( 1.1 )...
Chronic lymphocytic leukemia with 17P deletion as detected by an FDA-approved test, after at least one prior therapy
1 INDICATIONS AND USAGE Zydelig is indicated, in combination with rituximab, for the treatment of patients with relapsed chronic lymphocytic leukemia (CLL) for whom rituximab alone would be considered appropriate therapy due to other...
CAMPATH is indicated as a single agent for the treatment of B-cell chronic lymphocytic leukemia (B-CLL). CAMPATH is a CD52-directed cytolytic antibody indicated as a single agent for the treatment of B-cell chronic lymphocytic leukemia...
DailyMed labelCOPIKTRA is indicated for the treatment of adult patients with relapsed or refractory chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL) after at least two prior lines of systemic therapy. Limitations of Use:...
DailyMed labelIMBRUVICA is a kinase inhibitor indicated for the treatment of: Adult patients with chronic lymphocytic leukemia (CLL)/Small lymphocytic lymphoma (SLL) ( 1.1 ). Adult patients with chronic lymphocytic leukemia (CLL)/Small lymphocytic...
DailyMed labelINDICATIONS AND USAGE LEUKERAN (chlorambucil) is indicated in the treatment of chronic lymphatic (lymphocytic) leukemia, malignant lymphomas including lymphosarcoma, giant follicular lymphoma, and Hodgkin’s disease. It is not curative...
DailyMed labelVENCLEXTA is a BCL-2 inhibitor indicated: For the treatment of adult patients with chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL). ( 1.1 ) In combination with azacitidine, or decitabine, or low-dose cytarabine...
DailyMed labelZydelig is indicated, in combination with rituximab, for the treatment of patients with relapsed chronic lymphocytic leukemia (CLL) for whom rituximab alone would be considered appropriate therapy due to other co-morbidities. Zydelig is...
DailyMed label